Sawai Group Holdings (4887 JP): FY23 Result Missed Guidance; FY24 Guidance Calls For Lower Profits
In FY23, Sawai’s revenue, operating profit, and net profit missed guidance. In FY24, core operating income is projected to decline due to the...
Top APAC (Ex-China) Investment Worthy Healthcare Companies Using Smartkarma’s Smart Score Screener
We have screened APAC (ex-China) healthcare companies with market cap≥$800M using Smartkarma’s Smart Score and picked up 2 investable ideas by...
Sawai Group Holdings (4887 JP): Continued Price Erosion Is Weakening Earnings Prowess
In H1FY23, revenue from Japan declined 7%, mainly due to drug price revisions in several consecutive years. Generic drug makers are more affected...
2022 JPX Nikkei 400 Rebal Update - Going the Right Way
JPX Nikkei 400 rebalance is going the right way in the 6 trading days so far, and it wasn't done on Day1 (which was lacklustre). It may be under...
No more insights